Table 1 Patient Characteristics (N = 234).

From: Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer

Characteristic

Total

TS expression

N (%)

Positive (N = 115)

Negative (N = 119)

P-value

Age

≥65 years

80 (34.2%)

45 (39.1%)

35 (29.4%)

0.118

Male sex

 

132 (56.4%)

74 (64.3%)

58 (48.7%)

0.016

Smoking

    

0.004

 

Never smoker

106 (45.3%)

42 (36.5%)

64 (53.8%)

 
 

Former smoker

78 (33.3%)

39 (33.9%)

39 (32.8%)

 
 

Current smoker

50 (21.4%)

34 (29.6%)

16 (13.4%)

 

EGFR mutation

    

0.015

 

Positive

77 (32.9%)

28 (24.3%)

49 (41.2%)

 
 

Negative

143 (61.1%)

81 (70.4%)

62 (52.1%)

 
 

Unknown

14 (06.0%)

6 (5.2%)

8 (6.7%)

 

ALK rearrangement

    

0.822

 

Positive

14 (06.0%)

4 (3.5%)

10 (8.4%)

 
 

Negative

219 (93.6%)

110 (95.7%)

109 (91.6%)

 
 

Unknown

1 (00.4%)

1 (0.9%)

0 (0.0%)

 

Treatment

    

0.303

 

Pemetrexed/cisplatin

124 (53.0%)

57 (49.6%)

67 (56.3%)

 
 

Gemcitabine/cisplatin

110 (47.0%)

58 (50.4%)

52 (43.7%)

 

SUVmax

Mean ± SD

10.2 ± 4.8

10.7 ± 5.0

9.6 ± 4.5

0.086

MTV

Mean ± SD

58.5 ± 92.2

64.7 ± 97.7

44.7 ± 69.8

0.074

TLG

Mean ± SD

309.7 ± 539.9

351.9 ± 583.5

225.1 ± 371.9

0.048

Progression

 

212 (90.6%)

108 (93.9%)

104 (87.4%)

0.080

Death

 

104 (44.4%)

64 (55.7%)

40 (33.6%)

0.001

PFS

Median, IQR (months) 5.6, 3.2–7.4

5.5, 3.3–6.9

6.1, 3.0–8.9

0.060

OS

Median, IQR (months) 13.7, 7.5–21.3

11.4, 6.7–18.2

15.8, 10.0–25.6

0.001

  1. EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; TS, thymidylate synthase; SUVmax, maximum standard uptake value; SD, standard deviation; MTV, metabolic tumor volume; TLG, total lesion glycolysis; PFS, progression-free survival; IQR, interquartile range; OS, overall survival.
Back to article page